Saturday, August 15, 2020 5:16:53 PM
There is a higher-up to consider.
I didn't elaborate on the socio-political implications of an Australian approval of blarcamesine for Alzheimer's.
Of course, if this happens (very, very likely), a lot of questions by a lot of people will be asked.
Those with family members with Alzheimer's (been there, watched my dad die of it) will be asking, "Why can't we have this? All we have are a few weak drugs that only slightly slow the progression of the disease. We wanna try what the Aussies have." But their questions will be no more addressed than those we post on this message board.
But there is one person to whom the head of the Food and Drug Administration is accountable, the person who presides over the entire executive branch of the federal government. You know who.
What might happen of this person finds that Australia has begun to treat Alzheimer's patients with a successful drug not yet approved by the FDA. In his view, do you suppose expedited approval of blarcamesine would Make America Great (or healthy) Again?
Wouldn't ya love to listen in on the conversation with the Presider and the head of the FDA? "Now listen to me very carefully....!"
Is our FDA going to be so pompous as to not have high level discussions about 2-73?
Of course, if this happens (very, very likely), a lot of questions by a lot of people will be asked.
Those with family members with Alzheimer's (been there, watched my dad die of it) will be asking, "Why can't we have this? All we have are a few weak drugs that only slightly slow the progression of the disease. We wanna try what the Aussies have." But their questions will be no more addressed than those we post on this message board.
But there is one person to whom the head of the Food and Drug Administration is accountable, the person who presides over the entire executive branch of the federal government. You know who.
What might happen of this person finds that Australia has begun to treat Alzheimer's patients with a successful drug not yet approved by the FDA. In his view, do you suppose expedited approval of blarcamesine would Make America Great (or healthy) Again?
Wouldn't ya love to listen in on the conversation with the Presider and the head of the FDA? "Now listen to me very carefully....!"
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
